GLP‑1 Inhibitors for Weight Management: Semaglutide and Tirzepatide
Glucagon‑like peptide‑1 (GLP‑1) inhibitors are a class of medications originally developed for type 2 diabetes that have become highly effective tools for chronic weight management and obesity treatment. These agents mimic the effects of the natural GLP‑1 hormone, which regulates appetite, glucose levels, and gastrointestinal motility.

Benefits
• Significant weight reduction: Both semaglutide (brand names: Wegovy®, Ozempic®) and tirzepatide (brand names: Mounjaro®, Zepbound®) can result in 15–20% average weight loss with proper diet and lifestyle modifications.
• Improved metabolic health: They enhance insulin sensitivity, reduce fasting glucose, and lower HbA1c, helping prevent or manage diabetes.
• Cardiovascular benefits: Trials show reduced risk of major cardiovascular events in high‑risk populations, including those with obesity or diabetes.
• Appetite regulation: These medications act on central receptors to reduce hunger and cravings, promoting sustainable satiety.
• Potential improvements in fatty liver disease, blood pressure, and inflammation have also been observed.
Contraindications
GLP‑1 inhibitors should not be used in the following circumstances:
• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
• Prior severe hypersensitivity or allergic reaction to the medication.
• Pregnancy or intent to become pregnant.
• History of pancreatitis (use with caution or avoid if recurrent).
• Severe gastrointestinal disease such as gastroparesis.
Patients with kidney disease, gallbladder disease, or taking insulin or sulfonylureas should use GLP‑1 inhibitors under close medical supervision to minimize risk of hypoglycemia or other adverse effects.

• I understand that GLP‑1 medications are not a guarantee of weight loss and results vary.
• I understand potential side effects may include nausea, vomiting, diarrhea, constipation, reflux, fatigue, and injection site reactions.
• I understand compounded medications are not FDA‑approved but are legally prescribed when clinically appropriate.
• I understand I must follow dosing instructions and attend follow‑up visits as recommended.
• I confirm I am physically located in an eligible state at the time of my visit.
• I understand payment, membership, and refill policies apply.